CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 44 enrolled
Drug / intervention
Take samplesother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02800382
NCT02800382N/ACompleted
CompareCT.gov

Bronchoalveolar Lavage Liq To Distinguish Benign and Malignant Pulmonary Diseases

Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital·interventional·Posted Jun 15, 2016·Updated Jun 15, 2016

In Brief

A clinical study evaluating Take samples for Lung Diseases. Completed, enrolled 44 participants.

Detailed Summary

Lipid per oxidation final products and free oxygen radicals are thought as initiator role for developing of cancer in the body. Level of paraoxonase in the patients with cancer varies. In this research, the investigators investigated the contribution of level of serum and bronchoalveolar lavage paraoxonase in the differentiation of benign and malignant lung disease patients. This research includes the patients that are diagnosis of lung cancer (research group) and benign pulmonary disease (control group) participated by accepted fiberoptic bronchoscopy (FOB).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Diseases
Countries--
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 15, 2016
Enrollment StartJan 1, 2012
Primary CompletionDec 1, 2013
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.0 years ago

Interventions

Take samplesother

Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.